Pharmacokinetic and Safety Profiles of MIT-001, a Novel Ferroptosis Inhibitor, After Subcutaneous Administration in Healthy Participants
The systemic exposure of MIT-001 after SC administration increased linearly across the dose levels of 10-40 mg. MIT-001 was well tolerated after a single SC dose of 10-40 mg and multiple SC doses of 20-40 mg in healthy participants.
Authors
- Kyung‐Sang Yu (ORCID: https://orcid.org/0000-0003-0921-7225)
- Sujong Lee
- Sungyeun Bae (ORCID: https://orcid.org/0000-0002-6584-9158)
- SeungHwan Lee (ORCID: https://orcid.org/0000-0002-1713-9194)
Institutions
- Seoul National University (KR)
- Seoul National University Hospital (KR)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-09-01
- DOI
- https://doi.org/10.2147/dddt.s541415
- Primary Topic
- Oral health in cancer treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00